ArticleInternational journal of preventive medicine2026
A Scientometric Mapping of Global Lenacapavir and HIV Research: Dynamism, Visualization, and Emerging Patterns.
Article in International journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lenacapavir, an HIV capsid inhibitor, has shown powerful promise for HIV treatment and prevention purposes. Its new mechanism of action, and other abilities to inhibit viral replication have shown a significant advance, especially in treatment-resistant cases. This bibliometric analysis aimed to assess the scientific literature that relates to lenacapavir particularly around HIV treatment and prevention efforts. Methods: Following the RAMIBS guidelines, a comprehensive literature search was conducted on January 8, 2025, using Scopus. The search included documents mentioning "lenacapavir" or its synonyms combined with HIV-related terms published between 2019 and 2025. Documents not meeting these criteria or unavailable in full text were excluded. Data were analyzed using VOSviewer for keyword co-occurrence, Bibliometrix for descriptive and network analysis, and SciVal for advanced impact metrics. Results: A total of 156 documents from 101 sources were analyzed, showing an annual growth rate of 89.86%. The average document age was 2.03 years, with 12.29 citations per document. The study involved 990 authors, with an average of 8.36 co-authors per document and 24.36% international co-authorship. Gilead Sciences, Inc., and the University of Washington were the prominent contributors. Key journals included "Current Opinion in HIV and AIDS" and "Journal of Antimicrobial Chemotherapy." The USA led the international collaboration. Conclusions: This study highlights the significant scientific output and collaboration in the field of lenacapavir and HIV research. The findings are useful for identifying key sources and authors, facilitating future research and collaboration. The findings highlight how crucial international collaboration is for driving progress in scientific research and tackling worldwide health issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.